To examine whether TM4SF5-mediated tumor formation in immune-competent mice might be also targeted by the TSI, we liver-orthotopically injected SNU449Cp or SNU449T7 cells into WT C57BL/6 female mice (n = 4) 1 week before starting 2-week treatment with vehicle DMSO or ST-5-002 (Supplementary Fig. S8a). This evidence concerns the gene TM4SF5 and neoplasm.